Oxford BioDynamics and Google Cloud Agree to Collaborate and Help Accelerate Cloud-Based Analytical Frameworks for Precision Medicine
Oxford BioDynamics (OBD), a biotechnology company pioneering the use of 3D genomic biomarkers for clinical diagnostics, is pleased to announce that it is collaborating with Google Cloud to support the development and deployment of OBD’s cutting-edge analytical framework on the cloud.
Through this collaboration, Google Cloud will provide support via cloud computing, enabling OBD to scale its proprietary EpiSwitch® knowledge space and analytical tools and deliver high-throughput, AI-powered 3D genomic analytics in a secure, efficient, and globally accessible environment to the benefit of its pharma and biotech partners. This effort marks an important milestone in OBD’s digital transformation and utilisation of its knowledge base and reflects Google Cloud’s commitment to empowering innovative life sciences research through its advanced cloud infrastructure.
Iain Ross, Executive Chairman of OBD said “Working with Google Cloud allows OBD to rapidly scale its analytical capabilities, bringing it closer to delivering precision 3D genomics insights in real time. Since joining the company, I have been convinced of the value of our 3D Genomics knowledgebase and the formation of this collaboration with Google Cloud only serves to validate this view. We are excited to develop a powerful and interoperable platform that aligns with the future of cloud-native biomedical research. Google Cloud’s global infrastructure allows us to share insights faster, collaborate more easily with our partners, and bring our predictive genomic tools into clinics and labs around the world — at scale.”
OBD’s growth trajectory across translational research, diagnostic development, and strategic partnerships is the key impetus for this collaboration with Google Cloud. The allocated resources will support containerized deployment, integration with Google Cloud’s AI/ML tools, and secure, scalable data processing pipelines that meet healthcare compliance standards which will make the OBD platform more accessible to pharma and biotech companies and create future opportunities to commercialise the EpiSwitch platform.
OBD will provide access to its EpiSwitch® platform, a clinically validated technology that reveals regulatory 3D genome architecture changes, enabling the detection of complex disease signatures, disease understanding and target development.
OBD will work closely to monitor resource usage and performance benchmarks, ensuring a scalable and cost-effective model for ongoing innovation.
- Deprivation and transport density linked to increased suicide risk in England - 15th August 2025
- Over a Third of UK Professionals Start Work Earlier or Finish Later Every Day - 15th August 2025
- Oxford BioDynamics and Google Cloud Agree to Collaborate - 15th August 2025
